Last reviewed · How we verify
Anti-PD-1 Checkpoint Inhibitor
Anti-PD-1 Checkpoint Inhibitor is a Checkpoint Inhibitor Biologic drug developed by Istari Oncology, Inc.. It is currently in Phase 2 development for Non-small cell lung cancer, Melanoma.
Inhibits PD-1 receptor
Inhibits PD-1 receptor Used for Non-small cell lung cancer, Melanoma.
At a glance
| Generic name | Anti-PD-1 Checkpoint Inhibitor |
|---|---|
| Sponsor | Istari Oncology, Inc. |
| Drug class | Checkpoint Inhibitor |
| Target | PD-1 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
PD-1 inhibitors block the PD-1 receptor on T cells, preventing its interaction with PD-L1 and allowing the immune system to attack cancer cells.
Approved indications
- Non-small cell lung cancer
- Melanoma
Common side effects
- Pneumonitis
- Colitis
- Hypothyroidism
Key clinical trials
- Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors (PHASE1)
- A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma (PHASE1)
- A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC (PHASE1, PHASE2)
- Comparing the Combination of Sullumab and Fruquintinib in Postoperative Adjuvant Therapy for High Recurrence Risk Non Transparent Renal Cell Carcinoma (PHASE2)
- Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy (PHASE1)
- Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer. (PHASE2)
- Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC (PHASE2)
- Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-PD-1 Checkpoint Inhibitor CI brief — competitive landscape report
- Anti-PD-1 Checkpoint Inhibitor updates RSS · CI watch RSS
- Istari Oncology, Inc. portfolio CI
Frequently asked questions about Anti-PD-1 Checkpoint Inhibitor
What is Anti-PD-1 Checkpoint Inhibitor?
Anti-PD-1 Checkpoint Inhibitor is a Checkpoint Inhibitor drug developed by Istari Oncology, Inc., indicated for Non-small cell lung cancer, Melanoma.
How does Anti-PD-1 Checkpoint Inhibitor work?
Inhibits PD-1 receptor
What is Anti-PD-1 Checkpoint Inhibitor used for?
Anti-PD-1 Checkpoint Inhibitor is indicated for Non-small cell lung cancer, Melanoma.
Who makes Anti-PD-1 Checkpoint Inhibitor?
Anti-PD-1 Checkpoint Inhibitor is developed by Istari Oncology, Inc. (see full Istari Oncology, Inc. pipeline at /company/istari-oncology-inc).
What drug class is Anti-PD-1 Checkpoint Inhibitor in?
Anti-PD-1 Checkpoint Inhibitor belongs to the Checkpoint Inhibitor class. See all Checkpoint Inhibitor drugs at /class/checkpoint-inhibitor.
What development phase is Anti-PD-1 Checkpoint Inhibitor in?
Anti-PD-1 Checkpoint Inhibitor is in Phase 2.
What are the side effects of Anti-PD-1 Checkpoint Inhibitor?
Common side effects of Anti-PD-1 Checkpoint Inhibitor include Pneumonitis, Colitis, Hypothyroidism.
What does Anti-PD-1 Checkpoint Inhibitor target?
Anti-PD-1 Checkpoint Inhibitor targets PD-1 and is a Checkpoint Inhibitor.
Related
- Drug class: All Checkpoint Inhibitor drugs
- Target: All drugs targeting PD-1
- Manufacturer: Istari Oncology, Inc. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Non-small cell lung cancer
- Indication: Drugs for Melanoma